Emergent BioSolutions (EBS) Non-Current Deffered Revenue (2010 - 2022)

Emergent BioSolutions' Non-Current Deffered Revenue history runs 11 years deep, the most recent figure standing at $5.9 million for Q1 2022.

• In Q1 2022, Non-Current Deffered Revenue fell 88.76% year-over-year to $5.9 million; the TTM figure through Mar 2022 stood at $5.9 million (down 88.76% YoY), while the FY2021 annual figure was $4.7 million, down 91.53% from the prior year.
• Non-Current Deffered Revenue was $5.9 million for Q1 2022 at Emergent BioSolutions, up from $4.7 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $85.6 million in Q4 2019 to a low of $4.7 million in Q4 2021.
• Historically, Non-Current Deffered Revenue has averaged $59.0 million across 5 years, with a median of $62.5 million in 2018.
• The sharpest annual moves came in 2018 and 2021: Non-Current Deffered Revenue jumped 327.49% in 2018, then slumped 91.53% in 2021.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $62.5 million in 2018, then jumped by 36.96% to $85.6 million in 2019, then tumbled by 35.16% to $55.5 million in 2020, then plunged by 91.53% to $4.7 million in 2021, then grew by 25.53% to $5.9 million in 2022.
• The last three Non-Current Deffered Revenue figures came in at $5.9 million (Q1 2022), $4.7 million (Q4 2021), and $45.3 million (Q3 2021), per Business Quant data.